Overactive Bladder (OAB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Overactive Bladder (OAB) Market Outlook

Thelansis’s “Overactive Bladder (OAB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Overactive Bladder (OAB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Overactive Bladder (OAB) Overview

The International Continence Society defines overactive bladder (OAB) as a syndrome characterized by urinary urgency, often accompanied by increased frequency and nighttime urination (nocturia), with or without the presence of urgency urinary incontinence (UI), and in the absence of urinary tract infection (UTI) or evident pathology. OAB can manifest with or without incontinence, termed OAB (wet) and OAB (dry). The exact cause of overactive bladder is not thoroughly understood, but it is believed to result from a combination of factors. The lower urinary tract serves two primary functions: storing and eliminating urine. The interplay between these functions is controlled by a network of neurotransmitters operating through both autonomic and somatic pathways. When involuntary contractions of the detrusor muscle, known as detrusor overactivity, occur spontaneously or in response to stimuli, as observed during urodynamic assessments, it leads to the development of an overactive bladder, with or without accompanying incontinence. Around 90% of cases involving detrusor overactivity causing symptoms of urgency and frequency, with or without incontinence, are idiopathic in nature, lacking an identifiable cause. Nonetheless, neurological issues, anatomical irregularities within the lower urinary tract, and other disorders can contribute to or worsen detrusor overactivity. Relevant diagnostic measures comprise urinalysis and, if irritative bladder symptoms and significant microhematuria are present on urinalysis, potentially urine cytology. Conditions like UTIs and chronic irritative bladder ailments can mimic the symptoms of OAB. The assessment of postvoid residual volume (typically <150 mL) can assist in ruling out overflow incontinence. The management of overactive bladder encompasses addressing any underlying and reversible medical conditions that contribute to the syndrome. This might involve employing antibiotics for bladder infections, addressing stress UI through surgical, weight-related, or medical interventions, and optimizing glucose regulation in diabetes. The ultimate aim is to progress toward treatments that specifically target the symptoms related to the bladder.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources &amp; assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Overactive Bladder (OAB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034